|
Non
|
tert - Butyl 6 - [(1E)-2 - [4 - (4 - fluorofenil) - 6 - (1 - methylethyl) - 2 - [methyl (methylsulfonyl) amino] - 5 - pirimidinyl] ethenyl] - 2} - 2}} - 1,3 - dioxane - 4 - asetat
|
|---|---|
|
Sinonim
|
(4R,6S)-6-[(1E)-2-[4-(4-FLUOROPHENYL)-6-(1-METHYLETHYL)-2-[METHYL(METHYLSULFONYL)AMINO]-5-PYRIMIDINYL]ETENIL]-2,2-DIMETHYL-1,3-DIOXANE-1,3-DIOXANE-DIMETHYLE1-DIOXANE ESTER;
tert - Butyl 6 - [(1E)-2 - [4 - (4 - fluorofenil) - 6 - (1 - methylethyl) - 2 - [methyl (methylsulfonyl) amino] - 5 - pirimidinyl] ethenyl] - 2} - 2}} - 1,3 - dioxane - 4 - asetat;
6 - [(1E)-2 - [4 - (4 - Fluorofenil) - 6 - (1 - methylethyl) - 2 - [methyl(methylsulfonyl)amino] - 5 - pirimidinyl]etenyl] - 2,2 - dimethyl},{10}} dimethyl}{10}} dimethyl}{1}} {1} dimetil} - 4 - asid acetic 1,1 - dimethylethyl ester; Rosuvastatin entèmedyè R - 2; Tert - Butyl (+) - 7 - [4 - (4 - Fluorophenyl) - 6 - Isopropyl - 2 - (N - Methyl - N {- Methyl Sulfonlyamino) Pirimidin {{27}{2}}}} ({27}{25}}}} - Dioxane - (E) - 6 - Heptenoate; Tert - butil (+) - 7 - [4 - (4 - fluorofenil) - 6 - izopropil - 2 - (n - metil - n - metilsulfonil amino) pirimidin - 5 -5}] - 5 - 5}] - 5 - 5} } 3 - 5 -5} dioxane - (e) - 6 - heptenate;
Tèt - butil (-) - 7 - [4 - (4 - fluorofenil) - 6 - izopropil - 2 - (N - metil - N - methylsulfonylamino)pirimidin - 5 - yl] {{1} diksan -}} - (E) - 6 - heptenate; Tert - butil (-) - 7 - [4 - (4 - afluorofenil) - 6 - izopropil - 2 - (N - metil - N - methylsulfonylamino) pirimidin {{},{24}} - metilsulfonilamino - methylsulfonylamino - {}, R7} {2}- 7 -- 7 -- 7 -- 7 -- 7 -- 7 -}}- 7 -}} - dioxane - (E) - 6 - heptenate
|
|
Nimewo CAS
|
289042 - 12 - 2
|
|
MF
|
C₂₉H₄₀FN₃O₆S
|
|
mw
|
577.71
|
|
EINECS No.
|
1806241 - 263 - 5
|
|
Pwen k ap fonn
|
153 - 155 degre
|
|
Pwen bouyi
|
673.3±65.0 degre (Prevwa)
|
|
Dansite
|
1.210
|
|
Kondisyon Depo
|
Atmosfè inaktif, 2 - 8 degre
|
|
Solibilite
|
Yon ti kras idrosolubl nan klowofòm, yon ti kras idrosolubl nan metanol
|
|
Konstant Disosyasyon Asid (pKa)
|
-0.43±0.10 (Prevwa)
|
|
Fòm
|
Solid
|
|
Koulè
|
Blan ak - blan
|
|
Itilizasyon
|
1. Nwayo Entèmedyè pou Sentèz kalsyòm Rosuvastatin: Kòm yon précurseur kle nan pwodiksyon dwòg sa a lipid -bese, li ka konstwi estrikti molekilè debaz nan rosuvastatin kalsyòm atravè reyaksyon ki vin apre tankou idroliz ak sikilasyon, k ap sèvi kòm yon lyen endispansab nan wout sentèz dwòg la.
2. Zouti pou Optimizasyon R&D famasetik: Nan amelyorasyon pwosesis rosuvastatin kalsyòm oswa R&D nan dwòg ki sanble lipid -bese, li ka aji kòm yon matyè premyè debaz pou modifikasyon estriktirèl. Li ede ajiste pwopriyete kle nan konpoze tankou solubility lipid ak estabilite metabolik, fasilite devlopman nan nouvo dwòg oswa pwosesis amelyore.
3. Entèmedyè pou reyaksyon òganik sentèz: ak gwoup fonksyonèl tankou gwoup ester ak gwoup vinil, li ka patisipe nan divès reyaksyon transfòmasyon òganik. Pi lwen pase sentèz pharmaceutique, li se tou itilize sentèz dérivés carboxylate estriktirèl ki sanble, ki aplike nan R & D nan pwodwi chimik amann.
|
Baj popilè: cas:289042-12-2 tert-butil 6-[(1e)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]etenyl]-2,2-dimethyl-1,4-dimethyl-1,4-dimethyl-1,4-faktor, distribitè Lachin koutim, wholesale